Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

Stein Mark N.; Hirshfield Kim M.; Zhong Hua; Singer Eric A.; Ali Siraj M.; Ganesan Shridar

首页> 外文期刊>European urology >Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

【24h】

Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

机译：Tivantinib进展后对MET突变型乳头状肾细胞癌患者对Crizotinib的反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2015年第2期|共2页
作者
Stein Mark N.; Hirshfield Kim M.; Zhong Hua; Singer Eric A.; Ali Siraj M.; Ganesan Shridar;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
入库时间 2022-08-18 10:59:33

相似文献

外文文献
中文文献
专利

1. Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib [J] . Stein Mark N., Hirshfield Kim M., Zhong Hua, European urology . 2015,第2期

机译：Tivantinib进展后对MET突变型乳头状肾细胞癌患者对Crizotinib的反应
2. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer [J] . Sakakibara-Konishi Jun, Kitai Hidenori, Ikezawa Yasuyuki, Clinical lung cancer . 2019,第5期

机译：在患有ALK重新排列的非小细胞肺癌的患者中洛拉替尼的进展后的蠕动后重新施用
3. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial [J] . Schoffski Patrick, Wozniak Agnieszka, Escudier Bernard, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：Crizotinib在先进的乳头肾细胞癌中达到持久的疾病控制，1型均突变或扩增患者。 Eortc 90101创建试用
4. Changes of the total antioxidative status of blood cells in the progression of stomach and large bowel cancers in patients subjected to primary radical treatment [C] . Z. Kopanski, J. Bertrandt, M. Grabowska, International Conference on Food Factors . 2004

机译：患者初级自由基治疗中胃癌和大肠癌进展中血细胞总抗氧化状态的变化
5. Understanding the Attributes of Papillary Renal Cell Carcinoma subtypes: Molecular Analysis, Biomarker Discovery and Implications to Therapy [D] . Saleeb, Rola Magdy Yousef. 2018

机译：了解乳头状肾细胞癌亚型的属性：分子分析，生物标志物发现及其对治疗的意义
6. Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib [O] . Mark N. Stein, Kim M. Hirshfield, Hua Zhong, -1

机译：Tivantinib进展后MET突变型乳头状肾细胞癌患者对Crizotinib的反应
7. Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK ‐positive non‐small‐cell lung cancer: Case report and review of the literature [O] . Nathaniel E. Wiest, Katherine S. Tzou, Matthew T. Olson, 2021

机译：Crizotinib相关的肾囊肿开发可能与alk阳性非小细胞肺癌患者的延长进展生存有关：病例报告和文献审查

Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

著录项

相似文献

相关主题

期刊订阅